Displaying 44 (all) recruiting clinical trials.
-
A Phase 1b/2 Open-Label Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Castrate Resistant Prostate Cancer
The purpose of the study is to determine the safety and efficacy of the treatments: AB928, a novel adenosine receptor blocker, plus zimberelimab, an anti-PD1 ... -
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ... -
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be ... -
A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
The purpose of the study is to determine the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine ... -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
The purpose of the study is to determine if M3814 in combination with radiation therapy and avelumab is safe and tolerable in patients with advanced ... -
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ... -
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
The purpose of the study is to determine the safety and tolerability of investigational treatment combinations with or without pembrolizumab or pembrolizumab alone for the ... -
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
The purpose of the study is to assess the efficacy of investigational treatment arms (pembrolizumab monotherapy or a unique pembrolizumab-based/ non-pembrolizumab-based combination) in participants with ... -
A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to ...